highest dose of retatrutide in adults with obesity over 104 weeks in the group had 30.3% weight loss. Nearly 2/3 reached BMI < 30 1 in 3 reached BMI < 25 Introductory dosing for larger guys

Some said the popularity of retatrutide could be linked to the rising cost of licensed weight loss products such as Mounjaro

Beyond that, a head-to-head comparison from the SURMOUNT-5 trial illustrates the difference clearly: Participants taking tirzepatide lost an average of 20.2% of their body weight compared to 13.7% with semaglutide

That's still a workable approach if you're staying for several days

The most common side effects are also gastrointestinal (nausea, etc.), especially in the first few months

As of the date above, retatrutide is not approved for clinical use in the United Kingdom

19-24 As with exenatide, there is minimal risk of hypoglycemia when used with nonsecretagogue medications